Lung Cancer Canada is collecting data to support approval of crizotinib for ROS1+ non-small cell lung cancer in their country. Their deadline for submission is rapidly approaching, and they need more data to strengthen their case. They would like ROS1+ patients who have taking crizotinib to share the following information (no names): Demographic data (e.g., … Continue reading ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!
Members of The ROS1ders will be attending The International Association for the Study of Lung Cancer’s (IASLC) annual World Conference on Lung Cancer (WCLC) in Toronto, Canada, September 23-26, 2018. The Twitter hashtag for the conference is #WCLC2018. Presentations that will mention ROS1+ cancer are listed below. The abstract book containing these and other WCLC … Continue reading Presentations on ROS1+ Cancer at IASLC #WCLC2018
Thanks to Dr. H. Jack West for the shout-out to our ros1cancer.com website and our page Drugs to Treat ROS1+ Cancer! Time to highlight that we are now in an era when pts w/rare cancers are increasingly likely to know more than docs, even very good ones, about their dzs. This @ros1cancer page on Drugs … Continue reading The value of oncogene-focused patient-caregiver groups
Since I’ve been holding steady on my treatment, I haven’t needed access to a clinical trial yet. However, clinical trials may become essential to my survival, and I’m already concerned about getting into them when I need help the most. I often hear scientists ask, “how can we increase patient participation in clinical trials so … Continue reading The Unnecessary Cruelty of Clinical Trials by: Lisa Goldman
Dr. Sukhmani K. Padda, an assistant professor of medicine at Stanford University, discusses emerging therapeutic strategies for several rare mutations in NSCLC including ROS1. http://www.onclive.com/conference-coverage/mlcc-2018/novel-agents-emerging-for-lesserknown-targets-in-nsclc?p=1
Some researchers think combining immunotherapy and certain targeted therapies called tyrosine kinase inhibitors (TKIs) may be too toxic for patients. This Phase 1/2 study supports that idea. It combined nivolumab and full-dose crizotinib in ALK+ non-small cell lung cancer, and was discontinued for safety reasons when 38% of the first 13 patients developed liver problems … Continue reading Should we combine TKIs and immunotherapy?